The global blood processing devices and consumables market size was valued at USD 45.27 billion in 2022 and is anticipated to grow at a compound annual growth rate (CAGR) of 7.0% from 2023 to 2030. The market is witnessing a significant increase in demand, primarily driven by several key factors. These factors include the rising prevalence of infectious diseases necessitating blood transfusions and surgical interventions, as well as the growing population of elderly individuals who are more susceptible to various medical conditions requiring transfusions.
In addition, the sector is benefiting from the surge in research and development efforts focused on regenerative medicine and cell therapies, which are anticipated to further propel the demand for blood processing devices and consumables. According to World Health Organization (WHO), there are significant disparities in blood donation and transfusion patterns between high-income and low-income countries. High-income countries, despite having only 16% of the world's population, account for 40% of global blood donations. In these countries, most transfusions are given to individuals over 60 years of age, constituting up to 76% of all transfusions.
The market is expanding significantly because of the rising incidence of infectious disorders that call for surgical procedures and blood transfusions. The need for safe and efficient blood processing equipment and supplies, such as blood bags, filters, and centrifuges to support the transfusion process grows as the prevalence of infectious diseases rises. These equipment and supplies are essential for guaranteeing the reliability, safety, and efficacy of blood products used in medical treatments. The market is developing because of the increasing demand for these crucial products.
The growing population of elderly individuals has a significant impact on the market. As people age, they become more prone to various medical conditions that may require blood transfusions, such as surgeries, chronic diseases, and cancer treatments. This increased demand for blood transfusions among the elderly population drives the need for efficient and reliable blood processing devices and consumables. Healthcare facilities and blood banks must be equipped with the necessary equipment to process and store blood products to meet the growing demand. Consequently, the market is expanding to cater to the healthcare needs of the aging population.
According to WHO, countries worldwide are confronted with significant challenges as they strive to prepare their health and social systems to effectively respond to the demographic shift towards an aging population. By 2050, it is projected that 80% of older individuals will reside in low- and middle-income countries, underscoring the importance of adequate resources and support systems in these regions. The pace of population aging is unprecedented, with the number of people aged 60 and above surpassing that of children under 5 in 2020. Furthermore, the proportion of the global population aged 60 and above is anticipated to almost double from 12% in 2015 to 22% by 2050. This shift necessitates comprehensive planning and policies to address the evolving needs of older individuals and ensure their well-being and quality of life.
The COVID-19 pandemic has had a significant impact on the market. The implementation of lockdowns, social distancing measures, and travel restrictions resulted in the cancellation of blood drives and a decrease in blood donations. This led to a shortage of blood supply in many regions. In addition, the focus on treating COVID-19 patients and redirecting healthcare resources toward the pandemic further strained the availability of blood processing devices and consumables. The increased need for testing and screening for the virus also placed additional demands on blood processing equipment.
However, with the gradual easing of restrictions and the resumption of blood donation campaigns, the market is expected to recover as healthcare systems adapt and prioritize both COVID-19-related and non-COVID-19-related blood transfusions.
The devices segment accounted for the largest revenue share of around 60% in 2022. Technological advancements have led to the development of better and more user-friendly devices, improving performance, accuracy, and safety. The increasing demand for blood transfusions, driven by the growing prevalence of medical conditions and surgeries, requires reliable and efficient devices for processing blood components. Rising awareness of blood safety emphasizes the need for devices that ensure the separation and processing of blood components to maintain quality and safety. The aging population and the rise in chronic diseases contribute to the demand for devices to process blood components for elderly individuals and patients with chronic conditions. In addition, the growing healthcare expenditure and investments in healthcare infrastructure globally drive the adoption of advanced blood processing devices, enhancing patient care, and meeting the rising demand for transfusions. For instance, in 2021, U.S. healthcare spending increased by approximately 2.7%, amounting to USD 4.3 trillion or USD 12,914 per person.
The consumables segment is expected to grow at the fastest rate of 7.6% during the forecast period. The consumables segment in the global market is experiencing significant growth, primarily driven by the increased demand for blood transfusion procedures due to the growing prevalence of medical conditions, surgeries, and trauma cases. The rising emphasis on blood safety and the need for a sterile and contamination-free environment during blood collection, processing, and storage further fuels the demand for consumables. In addition, advancements in transfusion medicine, including apheresis and cellular therapies, require specialized consumables, contributing to the segment's growth. The increasing awareness about safe blood processing practices, coupled with stringent regulations and guidelines, drives the demand for high-quality consumables that meet safety standards.
For instance, in February 2020, a new action plan has been proposed by the World Health Organization (WHO) to fasten the process of access to secure blood and blood products worldwide. Through the consolidation of current suggestions and the introduction of improved tactics, this plan seeks to improve blood transfusion and blood-based therapies. The WHO will work with numerous stakeholders over the next four years to improve the availability of safe blood transfusions and treatments globally. Safe blood is necessary to save lives during disasters, epidemics, and other medical emergencies. It is essential for patients with life-threatening illnesses like cancer, thalassemia, immunological deficiencies, and hemophilia as well as for mothers and newborns during childbirth. In addition, it is essential for performing both medical and surgical procedures as well as treating serious injuries.
The other segment accounted for the highest revenue share of around 45% in 2022. The dominance of the "others" segment in terms of revenue in the market can be attributed to the significant contribution of blood banks. They play a vital role in collecting, storing, and processing blood products for transfusion purposes. They require specialized devices and consumables such as blood bags, centrifuges, filters, and blood grouping reagents to ensure the safety and quality of blood products. The demand for these devices and consumables from blood banks drives the growth of the "others" segment.
The increasing need for blood transfusions in healthcare settings, including surgeries, emergencies, and medical treatments, further fuels the demand for blood processing devices and consumables, contributing to the dominance of the "others" segment in terms of revenue. For instance, in March 2021, Grifols, S.A., a renowned global company specializing in plasma-derived therapies and advanced diagnostic solutions, has recently launched the DG Reader Net semi-automated analyzer in North America. This cutting-edge platform is specifically designed to optimize and enhance the process of blood type compatibility testing that is pre-transfusion, catering to the specific needs of blood banks. The successful implementation of the DG Reader Net analyzer at ThedaCare Medical Center-Wild Rose in Wisconsin marks its debut in the region. Grifols' dedication to delivering scalable and innovative solutions is evident in this latest addition to its product portfolio, aiming to improve the efficiency and accuracy of blood type compatibility testing in transfusion medicine. By advancing these capabilities, Grifols aims to make significant contributions to the enhancement of patient care within healthcare settings.
The diagnostic laboratories segment is estimated to register a CAGR of 8.3% over the forecast period. This is attributed to the increasing demand for diagnostic testing in healthcare settings has fueled the need for consumables in laboratories and clinics. These materials, including collection tubes, reagents, and slides, are essential for accurate and efficient testing procedures. Secondly, advancements in diagnostic technologies, such as molecular diagnostics and point-of-care testing, have created a greater demand for specialized consumables that support these advanced techniques. Moreover, the rising prevalence of chronic diseases worldwide has led to a surge in diagnostic testing, requiring a steady supply of consumables in diagnostic laboratories. The emphasis on quality and safety in diagnostics has further driven the demand for high-quality consumables that ensure accurate and reliable test results. In addition, government initiatives and healthcare investments aimed at expanding and modernizing diagnostic laboratories have contributed to the growth of the diagnostic laboratories’ material segment. These factors combined have propelled the segment to achieve a rapid pace in the market.
According to National Center for Biotechnology Information (NCBI), the U.S. is expected to witness a significant increase in its population aged 50 years and older, with a projected growth of 61.11% from 137.25 million in 2020 to 221.13 million in 2050. Within this age group, the number of individuals with at least one chronic disease is estimated to rise by 99.5%, reaching 142.66 million by 2050. In addition, the prevalence of multimorbidity, having multiple chronic conditions, is projected to increase by 91.16% from 7.8304 million in 2020 to 14.968 million in 2050. By 2050, approximately 64.6% of non-Hispanic whites, 61.47% of non-Hispanic blacks, and 64.5% of Hispanics and other races are expected to have one or more chronic conditions. These statistics highlight the growing healthcare needs and challenges posed by the aging population and the increasing burden of chronic diseases in the U.S.
North America dominated the market and accounted for the largest revenue share of 40% in 2022. North America's dominance in the market can be attributed to several driving factors. The region's strong focus on technological advancements and research and development has propelled it to the forefront of healthcare innovation, enabling the development and adoption of advanced blood processing devices and consumables. North America benefits from a well-established healthcare infrastructure comprising state-of-the-art hospitals, diagnostic laboratories, and blood banks. This robust healthcare system facilitates the efficient utilization and integration of blood processing devices and consumables, driving market growth.
In addition, the increasing prevalence of chronic diseases in North America has resulted in a higher demand for blood transfusions and related procedures. This demand for blood processing devices and consumables is fueled by the need to address the rising burden of conditions such as cardiovascular disorders, cancer, and diabetes. Moreover, favorable reimbursement policies and insurance coverage for blood processing procedures incentivize healthcare providers in North America to invest in advanced devices and consumables. This financial support creates a conducive environment for the adoption of innovative technologies, stimulating market growth.
Asia Pacific is expected to grow at the fastest CAGR of 8.4% during the forecast period. Asia Pacific is expected to witness the fastest growth in the blood processing devices and consumables market. This can be attributed to several key factors. The region's large and rapidly expanding population creates a higher demand for healthcare services, including blood processing devices and consumables. Increasing healthcare expenditure and government initiatives aimed at improving healthcare infrastructure in countries such as China and India drive the adoption of advanced blood processing technologies and consumables.
Moreover, the rising prevalence of chronic diseases in the region, such as diabetes, cardiovascular disorders, and cancer, contributes to the growing demand for blood transfusions and related procedures, boosting the market for blood processing devices and consumables. Furthermore, Asia Pacific experiences significant technological advancements and has a growing presence of local manufacturers offering cost-effective blood processing devices and consumables, improving product availability and affordability. These factors collectively drive the rapid growth of the market in the Asia Pacific.
For instance, the National Blood Transfusion Council (NBTC) of India was formed to ensure the availability of safe and quality blood and blood products throughout the country. The primary objectives of the NBTC include coordinating and promoting voluntary blood donation, establishing blood banks, setting standards for blood collection, testing, processing, storage, and distribution, as well as implementing quality control measures. The formation of the NBTC was crucial in addressing the need for a centralized authority to regulate and streamline blood transfusion services in India, ensuring the provision of a safe and adequate blood supply for patients in need.
Product launches, approvals, strategic acquisitions, and innovations are just a few of the important business strategies used by market participants to maintain and grow their global reach. For instance, in July 2020, Tasso, Inc., a company specializing in at-home blood collection devices, successfully raised funds for manufacturing its innovative product. The device allows individuals to collect blood samples in the comfort of their own homes, eliminating the need for traditional clinic-based blood draws. The raised funds will support the scaling up of manufacturing operations, enabling wider access to convenient blood collection, and advancing remote healthcare solutions. Tasso's technology has the potential to revolutionize the way blood samples are obtained, making healthcare more accessible and patient friendly. The following are some of the major participants in the global blood processing devices and consumables market:
Bio-Rad Laboratories, Inc.
F. Hoffmann-La Roche Ltd
ThermoGenesis Holdings, Inc.
Market size value in 2023
USD 48.29 billion
Revenue forecast in 2030
USD 77.71 billion
CAGR of 7.0% from 2023 to 2030
Base year for estimation
2018 - 2021
2023 - 2030
Revenue in USD billion and CAGR from 2023 to 2030
Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Product, end-use, region
North America; Europe; Asia Pacific; Latin America; MEA
U.S.; Canada; UK; Germany; France; Italy; Spain; Denmark; Sweden; Norway; China; Japan; India; Australia; South Korea; Thailand; Brazil; Mexico; Argentina; Saudi Arabia; South Africa; UAE; Kuwait
Key companies profiled
Biomerieux SA; Abbott; Bio-Rad Laboratories, Inc.; BD.; F. Hoffmann-La Roche Ltd; Danaher.; Immucor, Inc.; ThermoGenesis Holdings, Inc.; Grifols; S.A.; Terumo Corporation; Haemonetics Corporation; Macopharma
Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope
Pricing and purchase options
Avail customized purchase options to meet your exact research needs. Explore purchase options
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For the purpose of this study, Grand View Research has segmented the global blood processing devices and consumables market on the basis of product, end-use, and region:
Product Outlook (Revenue, USD Billion, 2018 - 2030)
End Use Outlook (Revenue, USD Billion, 2018 - 2030)
Hospitals and Clinics
Regional Outlook (Revenue, USD Billion, 2018 - 2030)
Middle East and Africa
b. The global blood processing devices and consumables market size was estimated at USD 45.27 billion in 2022 and is expected to reach USD 48.29 billion in 2023.
b. The global blood processing devices and consumables market is expected to grow at a compound annual growth rate of 7.0% from 2023 to 2030 to reach USD 77.71 billion by 2030.
b. North America dominated the blood processing devices and consumables market with a share of 39.5% in 2022. This is attributable to the presence of sophisticated healthcare infrastructure, prominent industry entities, and strong government support.
b. Some key players operating in the blood processing devices and consumables market include Biomerieux SA, Abbott Laboratories, Bio-Rad Laboratories, Becton, Dickinson And Company, Roche Holdings AG, Danaher Corporation, Immucor, Inc., Thermogenesis Corporation, Grifols International, Terumo Corporation, Haemonetics Corporation, and Macopharma SA.
b. Key factors that are driving the market growth include growing demand for blood transfusion, development of automated technology, and an increase in government initiatives.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
"The quality of research they have done for us has been excellent."